Media coverage about Marinus Pharmaceuticals (NASDAQ:MRNS) has been trending somewhat positive recently, Accern Sentiment reports. The research group identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Marinus Pharmaceuticals earned a news sentiment score of 0.11 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 46.3882779858949 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Here are some of the news articles that may have impacted Accern’s rankings:
- Guide to Analyst Recommendations: Marinus Pharmaceuticals, Inc. (MRNS) – Nasdaq Chronicle (nasdaqchronicle.com)
- Investors watching Technical Indicators on Marinus Pharmaceuticals, Inc. (MRNS) – Wall Street Morning (wallstreetmorning.com)
- Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) – Hot Stock’s Watch List – Nasdaq Journal (nasdaqjournal.com)
- Marinus Pharmaceuticals, Inc. (MRNS) Requires a Push to Attain Active Investors Attentions – Stock News Stop (stockmarketstop.com)
- Marinus Pharmaceuticals to Present at the Barclays Global Healthcare Conference (finance.yahoo.com)
Several research firms have commented on MRNS. Laidlaw began coverage on shares of Marinus Pharmaceuticals in a research report on Thursday, December 14th. They issued a “buy” rating and a $18.00 target price for the company. BidaskClub raised shares of Marinus Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, December 30th. ValuEngine lowered shares of Marinus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Finally, HC Wainwright assumed coverage on shares of Marinus Pharmaceuticals in a research note on Thursday, February 15th. They issued a “buy” rating and a $33.00 price target for the company. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $20.67.
Marinus Pharmaceuticals (NASDAQ:MRNS) last issued its quarterly earnings results on Tuesday, March 6th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.07).
In related news, CEO Christopher Michael Cashman sold 9,566 shares of the stock in a transaction that occurred on Thursday, January 18th. The shares were sold at an average price of $6.28, for a total transaction of $60,074.48. Following the completion of the sale, the chief executive officer now directly owns 247,903 shares of the company’s stock, valued at $1,556,830.84. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, major shareholder Bain Capital Life Sciences Inv sold 822,547 shares of the stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $8.10, for a total transaction of $6,662,630.70. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 2,107,660 shares of company stock valued at $16,774,106. Company insiders own 4.60% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This article was first reported by BBNS and is owned by of BBNS. If you are accessing this article on another publication, it was illegally copied and republished in violation of international copyright and trademark law. The original version of this article can be accessed at https://baseballnewssource.com/2018/03/14/marinus-pharmaceuticals-mrns-earning-somewhat-favorable-press-coverage-report-finds/2029800.html.
Marinus Pharmaceuticals Company Profile
Marinus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.
Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.